Show simple item record

dc.contributor.authorPaisley, Angela N
dc.contributor.authorTrainer, Peter J
dc.contributor.authorDrake, William M
dc.date.accessioned2009-08-20T11:31:19Z
dc.date.available2009-08-20T11:31:19Z
dc.date.issued2004-03
dc.identifier.citationPegvisomant: a novel pharmacotherapy for the treatment of acromegaly. 2004, 4 (3):421-5 Expert Opin Biol Theren
dc.identifier.issn1471-2598
dc.identifier.pmid15006735
dc.identifier.doi10.1517/14712598.4.3.421
dc.identifier.urihttp://hdl.handle.net/10541/77965
dc.description.abstractPegvisomant is a pegylated analogue of growth hormone (GH) that functions as a growth hormone receptor antagonist. Clinical trials of its use in acromegaly commenced in 1997; the drug was approved in the US in March 2003 and in Europe in November 2003. In the same year, it was made available on prescription in several European countries, with further launches due in 2004. Pegvisomant is capable of normalising serum insulin-like growth factor-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients with active acromegaly, and therapy is associated with a significant improvement in the symptoms and signs of GH excess. Disease control is achievable with pegvisomant in patients who are wholly or partially resistant or do not tolerate somatostatin analogues; preliminary data suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.
dc.language.isoenen
dc.subjectPituitary Canceren
dc.subject.meshAcromegaly
dc.subject.meshAnimals
dc.subject.meshHuman Growth Hormone
dc.subject.meshHumans
dc.subject.meshInsulin Resistance
dc.subject.meshPituitary Neoplasms
dc.subject.meshReceptors, Somatotropin
dc.titlePegvisomant: a novel pharmacotherapy for the treatment of acromegaly.en
dc.typeArticleen
dc.contributor.departmentDepartment of Endocrinology, Christie Hospital, Manchester, UK.en
dc.identifier.journalExpert Opinion on Biological Therapyen
html.description.abstractPegvisomant is a pegylated analogue of growth hormone (GH) that functions as a growth hormone receptor antagonist. Clinical trials of its use in acromegaly commenced in 1997; the drug was approved in the US in March 2003 and in Europe in November 2003. In the same year, it was made available on prescription in several European countries, with further launches due in 2004. Pegvisomant is capable of normalising serum insulin-like growth factor-I concentrations (the chief mediator of disease activity in acromegaly) in 97% of patients with active acromegaly, and therapy is associated with a significant improvement in the symptoms and signs of GH excess. Disease control is achievable with pegvisomant in patients who are wholly or partially resistant or do not tolerate somatostatin analogues; preliminary data suggest that the drug may be particularly suitable for patients with acromegaly and co-existent diabetes mellitus.


This item appears in the following Collection(s)

Show simple item record